// App-Quantinova.ai

663 : Phase 2 multi-cohort clinical study evaluating disitamab vedotin alone and in combination with pembrolizumab in patients with HER2-expressing unresectable or metastatic urothelial carcinoma (RC48G001, trial in progress)

Researchers

Presenter

  • Matthew Galsky

Principal Investigators

  • Peter O’Donnell

  • Earle Burgess

  • Michiel van der Heijden

  • Laurence Krieger

  • Andrea Necchi

  • Evan Yu

  • Nobuaki Matsubara

  • Matthew Campbell

  • Saikrishna Gadde

  • Jeanny Aragon-Ching

  • Vadim Koshkin

  • Wei Zhang

  • Kevin Sokolowski

  • Thomas Powles

Medical Centers

  • National Cancer Center Hospital East, Kashiwa/JP

  • Genesis Care, North Shore, Sydney, NSW, Australia

  • 1.MD Anderson Cancer Center, Houston, TX

  • Barts Health NHS Trust, London, UK

  • University of Tennessee Medical Center, Knoxville, TN

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • University of California, San Francisco, San Francisco, CA

  • Inova Schar Cancer Institute, Fairfax, VA

  • Univesity of Chicago, Chicago, USA

  • University of Washington, Seattle, WA

  • Vita-Salute San Raffaele University, Milan, Italy

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Atrium Health, Levine Cancer Institute, Charlotte, NC

Locations

  • Japan

  • United Kingdom

  • United States

  • Netherlands

  • Australia

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Advanced Urothelial Carcinoma

  • Solid malignancies

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

  • Cohort

Phase

  • II

Study Id's

  • NCT04879329

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved